Human IFN Beta ELISA Kit, High Sensitivity (Serum, Plasma, TCM)

Home / Products / Assay Kits / ELISAs / Human Interferon ELISAs / Human IFN Beta ELISA Kit, High Sensitivity (Serum, Plasma, TCM)
Product Features: 
  • ELISA assay measures human IFN beta with 1.2 pg/ml LOQ in serum, plasma, and tissue culture media (TCM)
  • Suitable for measurement of IFN-beta in autoimmune serum (link)
  • Suitable for measurement of trademarked interferon beta 1a and interferon beta 1b therapeutic molecules in human serum (link)
  • ELISA assay provides > 90% serum spike-recovery
  • Reproducible results with inter-assay CV < 8% and intra-assay CV < 10%
  • No inhibition of IFN beta detection by 3-log excess of soluble IFNAR2 protein

Full Product Name: VeriKine-HS Human Interferon Beta Serum ELISA Kit

Ordering

Catalog No. Pack Size Price Quantity
41415-1

1 x 96-well plate

 $765.00

Specifications

Compatibility: Serum, Plasma, Tissue Culture Media
ELISA Assay Range: 1.2 - 150 pg/ml
Speed: Incubation time, 3 hours, 30 minutes
Specificity: Human Interferon Beta 1a, Human Interferon Beta 1b (No cross-reactivity against human IFN-alpha, IFN-gamma, IFN-omega, IL-6; mouse IFN-alpha, IFN-beta; or rat IFN-beta.)
Synonyms: Human Beta Interferon, Human Fibroblast IFN, Human IFN Beta, Human Fibroblast Interferon, Human Beta IFN, Human Type I Interferon Beta, Human IFN B
 
Inter-Assay CV: < 8%
Intra-Assay CV: < 10%
Spike Recovery: > 90% in Serum
 
Storage: 2-8°C
Expiration Date: One year from date of manufacture
Shipping Condition: Wet Ice

Materials Provided:

  • Pre-coated microtiter plate
  • Plate Sealers
  • Wash Solution Concentrate
  • Human Interferon Beta 1a Standard, 100,000 pg/ml
  • Standard Diluent
  • Sample Buffer
  • Antibody Concentrate
  • HRP Conjugate Concentrate
  • Diluent Additive III
  • Assay Diluent
  • TMB Substrate
  • Stop Solution

Tech Info / Data

Image of human IFN beta standard concentration curve from 1.2 pg/ml to 150 pg/ml plotted against mean absorbance using PBL's High Sensitivity Human Interferon Beta ELISA kit, Protocol A
Image of human IFN beta standard concentration curve from 2.3 pg/ml to 150 pg/ml plotted against mean absorbance using PBL's High Sensitivity Human Interferon Beta ELISA kit, Protocol B
Image depicting the strong correlation between IFN beta standard curves prepared in Standard Diluent and in Pooled Normal Human Serum (NHS) using PBL's High Sensitivity Human Interferon Beta ELISA kit
Image showing that Standard Diluent is an excellent mimic of normal human serum (NHS) as shown by standard curves prepared in each, quantifying human IFN beta 1a using PBL's High Sensitivity Human Interferon Beta ELISA kit
Image showing that Standard Diluent is an excellent mimic of normal human serum (NHS) as shown by standard curves prepared in each, quantifying human IFN beta 1a using PBL's High Sensitivity Human Interferon Beta ELISA kit

Detailed Related Product Information:

Background: 

The High Sensitivity Human IFN Beta Serum ELISA Kit has been developed to measure low/basal levels of human IFN-beta in autoimmune sera,  normal serum/ plasma or tissue culture media samples by sandwich enzyme linked immunosorbent assay (ELISA). This assay is suitable for measurement of trademarked therapeutic molecules in human serum samples. Researchers and clinical investigators examining a) the pharmacokinetics of IFN-beta molecules, b) IFN-beta as a biomarker, or c) IFN-beta as a pharmacodynamic marker of TLR agent or other immune response modifier activity will find this highly sensitive and specific assay to be an essential laboratory tool.

Interferon beta (IFN-beta) is part of the first wave of cytokine response in cells. Pathogen infection can result in the activation of interferon regulatory factor 3 (IRF3) that functions in trans to activate IFN beta gene transcription. IFN-beta is biologically unique when compared to other interferons and studies have shown that IFN-beta has overlapping and distinct gene expression patterns as compared to IFN-alpha. It appears that IFN-beta binds to the Type I IFN receptor with higher affinity than the other Type I IFNs and it may also regulate receptor internalization in a different manner. Additionally, IFN-beta has long been known to inhibit viral replication as part of the body’s innate antiviral response and is used as a therapeutic for treatment of multiple sclerosis and some tumors.

Citations

Posters:

  1. Validation of a Highly Sensitive Immunoassay for the Quantitation of Interferon Beta in Autoimmune Sera (link)

  2. Optimization and Validation of an ELISA kit for the Quantification of Four Interferon-Beta (IFN-β) Marketed Compounds in Human Serum (link)

Citations:

  1. Clinical Study: Interferon Alpha Association with Neuromyelitis Optica. Asgari et al., 2013, Clinical and Developmental Immunology. 2013:1-6. (link)

  2. Influenza A virus-mediated priming enhances cytokine secretion by human dendritic cells infected with Streptococcus pneumoniae. Kuri et al., 2013, Cellular Microbiology. 15(8):1385-1400. (link)

  3. Site-Specific PEGylation Enhances the Pharmacokinetic Properties and Antitumor Activity of Interferon Beta-1b. Lee et al., 2013, Journal of Interferon and Cytokine Research. 33(12):769-77. (link)

  4. The physiologic increase in expression of some type I IFN-inducible genes during pregnancy is not associated with improved disease activity in pregnant patients with rheumatoid arthritis. Weix et al., 2013, Translational Research. 161(6):505-512. (link)

  5. Application of secretary luciferase labeled orthotopic transplant model of hepatocellular carcinoma to evaluate tumor response to interferon-β gene therapy. Wang et al., 2012, Sheng Wu Gong Cheng Xue Bao. 28(10):1236-1244. (link) (Article in Chinese)

  6. IFN-λ Inhibits HIV-1 integration and post-transcriptional events in vitro, but there is only limited in vivo repression of viral production. Tian et al., 2012, Antiviral Research. 95(1):57-65. (link)

  7. Interferon treatment suppresses enteric adenovirus infection in a model gastrointestinal cell-culture system. Sherwood et al., 2012, Journal of General Virology. 93:618-623. (link)

  8. Reduced DICER1 elicits an interferon response in endometrial cancer cells. Chiappinelli et al., 2012, Molecular Cancer Research. 10:316-325. (link)

  9. Human Papillomavirus Type 16 E5 Protein Induces Expression of Beta Interferon through Interferon Regulatory Factor 1 in Human Keratinocytes. Muto et al., 2011, Journal of Virology. 85(10):5070-5080. (link)

  10. IFN-β Mediates Suppression of IL-12p40 in Human Dendritic Cells following Infection with Virulent Francisella tularensis. Bauler et al., 2011, Journal of Immunology. 187:1845:1855. (link)

  11. Interferon Regulatory Factor 3 Inhibits Astrocyte Inflammatory Gene Expression Through Suppression of the Proinflammatory miR-155 and miR-155*. Tarassishin et al., 2011, GLIA. 59(12):1911-1922. (link)

  12. Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3K/Akt Pathway. Tarassishin et al., 2011, Journal of Neuroinflammation. 8:187. (link)

  13. Phagosomal signaling by Borrelia burgdorferi in human monocytes involves Toll-like receptor (TLR) 2 and TLR8 cooperativity and TLR8-mediated induction of IFN-β. Cervantes et al., 2011, Proceedings of the National Academy of Sciences. 108(9):3683-3688. (link)

References: (For additional references, please refer to the protocol booklet.)

  1. Krause et al. Pharmacol Ther. 2005; 106(3):299-346.

  2. Weinstock-Guttman et al. Expert Opin Biol Ther. 2008; 8(9):1435-47.

  3. Lee et al. Mol Cells. 2007; 23(1):1-10.

  4. Heim. J Recept Signal Transduct Res. 1999; 19(1-4):75-120.

Documentation

Levels of Interferon Beta Quantified in 128 Normal Donor and 54 Multiple Sclerosis (MS) Patient Sera Quantified using PBL's High Sensitivity Human IFN Beta ELISA (41415)

 

Image of human IFN Beta levels (pg/ml) in serum samples from 128 normal donors & 54 Multiple Sclerosis (MS) patients on & off IFN Beta therapies quantified by PBL's High Sensitivity Human Interferon Beta ELISA kit

IFN Beta is quantifiable in 86% of MS patients on IFN Beta therapy, 4.1% of MS patients on other therapies and 1.5% of Normal Donor samples.

Related Products

Catalog No. Description Pack Size Price Quantity
42410-1 VeriKine-HS Mouse Interferon Beta Serum ELISA Kit  new 
Compatibility: Serum, Plasma, Tissue Culture Media
Assay Range: 0.94-60 pg/ml

1 x 96-well plate

 $495.00
51510-1 VeriPlex Human Cytokine 16-Plex ELISA Kit
Compatibility: Serum, Plasma, Tissue Culture Media and Buffers
Assay Range: 2.86 log with LLOD and LLOQ in the low pg/ml range

1 x 96-well plate

 $1,675.00
11415-1 Human Interferon Beta 1a, mammalian

1 x 105 units

 $320.00
41115-1 VeriKine-HS Human Interferon Alpha All Subtype ELISA Kit  new 
Compatibility: Serum, Tissue Culture Media
Assay Range: 1.95-125 pg/ml

1 x 96-well plate

 $735.00
$785.00
41110-1 VeriKine Human Interferon Alpha Multi-Subtype Serum ELISA Kit
Compatibility: Serum, Plasma, Tissue Culture Media
Assay Range: 12.5-1000 pg/ml

1 x 96-well plate

 $695.00

Product Selector

Find your product of interest by searching for category, species, molecule and/or application.

Ahead of the Curve

Visit our blog to read about recent developments in the fields of interferon, cytokine and biomarker research!

Email Subscription

Sign up for our mailing list to be kept up-to-date on the latest promotions, company and product news.

Go to top